News | June 02, 2026
Ebola vax on the anvil?
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Includes thermostabilized Ebola vaccines
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
